Jaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued to investors on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Trading Up 14.7 %

JAGX opened at $0.18 on Monday. The company has a debt-to-equity ratio of 6.33, a quick ratio of 1.34 and a current ratio of 2.00. The business has a 50 day moving average of $0.09 and a 200-day moving average of $0.18. Jaguar Health has a 52 week low of $0.05 and a 52 week high of $1.22.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.